Medical Device News Magazine

Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm. Other participating investors include Series B Co-leads GL Ventures (venture capital arm of Hillhouse Group) and Sequoia Capital, and Series A lead VC Co-win Ventures.

Amador’s vision is to be a leading global partner for biotherapeutics R&D success,” said Dr. Bing Wang, Amador CEO and Chairman of the Board. “We strive to provide global-standard translational sciences and clinical pharmacology services to biopharmaceutical companies in the US, China and EU. Completion of the back-to-back Series B and B+ financing marks a key milestone mirroring the End-of-Phase 2 (EOP2) in drug development. With this achievement, we’re committed to expanding our team and business, while keeping Amador’s pledge to provide efficient and high-quality work. We are blessed with the trust and support of our biopharmaceutical clients, employees, collaborators, and in particular our distinguished institutional investors. Together we continue building an innovative and efficient engine to accelerate the global R&D of novel drugs.”

Amador expedited its development after the company closed Series B financing in September 2021. It recently acquired Ann Arbor Pharmacometrics Group (A2PG), a premier consulting firm specializing in advanced, efficient, and high-quality pharmacometrics analysis. In collaboration with Limburg Province of Belgium and Hasselt University, Amador Bioscience has established its EU headquarters on Corda Campus in Limburg and initiated an education program to train next-generation pharmacometricians. New facilities are currently under construction in the San Francisco Bay Area (Pleasanton, CA), the Maryland/DC area (Germantown, MD) and Ann Arbor, MI in the USA, and Xiaoshan (Hangzhou) in China. All are scheduled to open in Q1 or Q2 of 2022. A new business office in central Shanghai was opened in October 2021.

Funding from Amador’s Series B+ financing will allow the company to strengthen its clinical pharmacology business, expand global bioanalytical services, and further improve global early clinical development capabilities. Amador also plans to develop and implement AI and machine learning tools to facilitate clinical data analysis.

“We are optimistic about the overall technical capability and performance of Amador Bioscience,” said Mrs. Yu Zeng, Funding Partner of MSA Capital. “Amador is an excellent CRO in quantitative pharmacology and bioanalysis. As more first-in-class pharmaceutical projects launch in China, Amador Bioscience’s unique technical capabilities lead to substantial increase in its client base and market potential. Meanwhile, as a global CRO, Amador Bioscience has operation sites in the US and Europe. It is an expanding global company with a broad client base, the key characteristics of MSA-invested companies. Amador Bioscience recently completed its acquisition of a leading American pharmacometrics firm, A2PG. This acquisition represents a leap for global expansion of Amador Bioscience. We trust Dr. Bing Wang and his leadership team will take full advantage of this acquisition, continue to build up the company and its business, and become a model of globalization of Chinese CROs.”

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”